Evan Hall

@DrBetofMDPhD @StanfordCancer presents on TIL for patients with untreated brain metastases post PD-1 at #SMR24. Very important area to generate data. Time for TIL process, need for anesthesia/harvest, chemotherapy causing ⬇️plts, IL-2 etc complicate this scenario. 1/

Interesting work from @KashimaMDPhD @YaleCancer re: single cell analysis to look at mechanisms of ICI efficacy/resistance to ICI therapy in #kidneycancer. Phenotype of exhausted T cells may correlate with ICI efficacy. #ASCO24

@montypal @CityofHope_GU presenting early phase data of HIF-2-alpha drug DFF332 #ASCO24. Clearly an active and exciting class of rx for #ccRCC. As we see more early phase data from non-belzutifan candidates, will we identify differences in toxicity/SE profile or efficacy?

#ASCO24 @dsahil320 @MSKCancerCenter presenting important collab re: #chromophobe #RCC and outcomes with different types of 1L tx. Major effort to pool multi-institutional data, but very important as 99 pts is a large N for this dx. #kidneycancer

Inspiring talk from @fredhutch survivorship team member and melanoma survivor Barb Regis on importance of survivorship definition, thriving after surviving, integrating care with PCPs, and much more. Speaking at NW Melanoma Symposium @CureMelanoma